IDYA
Price
$25.40
Change
+$0.85 (+3.46%)
Updated
Sep 2, 10:36 AM (EDT)
Capitalization
2.15B
70 days until earnings call
SYRE
Price
$16.72
Change
+$0.23 (+1.39%)
Updated
Sep 2, 11:06 AM (EDT)
Capitalization
996.01M
65 days until earnings call
Interact to see
Advertisement

IDYA vs SYRE

Header iconIDYA vs SYRE Comparison
Open Charts IDYA vs SYREBanner chart's image
IDEAYA Biosciences
Price$25.40
Change+$0.85 (+3.46%)
Volume$1.66K
Capitalization2.15B
Spyre Therapeutics
Price$16.72
Change+$0.23 (+1.39%)
Volume$100
Capitalization996.01M
IDYA vs SYRE Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. SYRE commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (IDYA: $24.55 vs. SYRE: $16.49)
Brand notoriety: IDYA and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 64% vs. SYRE: 64%
Market capitalization -- IDYA: $2.15B vs. SYRE: $996.01M
IDYA [@Biotechnology] is valued at $2.15B. SYRE’s [@Biotechnology] market capitalization is $996.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 4 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -2.27% price change this week, while SYRE (@Biotechnology) price change was -5.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.59%, and the average quarterly price growth was +30.71%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.15B) has a higher market cap than SYRE($996M). IDYA YTD gains are higher at: -4.475 vs. SYRE (-29.167). SYRE has higher annual earnings (EBITDA): -222.15M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. SYRE (527M). SYRE has less debt than IDYA: SYRE (0) vs IDYA (26.6M). IDYA has higher revenues than SYRE: IDYA (7M) vs SYRE (0).
IDYASYREIDYA / SYRE
Capitalization2.15B996M216%
EBITDA-380.2M-222.15M171%
Gain YTD-4.475-29.16715%
P/E RatioN/A1.68-
Revenue7M0-
Total Cash670M527M127%
Total Debt26.6M0-
FUNDAMENTALS RATINGS
IDYA vs SYRE: Fundamental Ratings
IDYA
SYRE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5463
P/E GROWTH RATING
1..100
10084
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is in the same range as SYRE (72) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to SYRE’s over the last 12 months.

IDYA's Profit vs Risk Rating (70) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to SYRE’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to SYRE’s over the last 12 months.

IDYA's Price Growth Rating (54) in the null industry is in the same range as SYRE (63) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (84) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that SYRE’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYASYRE
RSI
ODDS (%)
Bearish Trend 5 days ago
78%
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
75%
Bearish Trend 5 days ago
86%
Momentum
ODDS (%)
Bullish Trend 5 days ago
76%
Bearish Trend 5 days ago
86%
MACD
ODDS (%)
Bearish Trend 5 days ago
72%
Bullish Trend 5 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 5 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 5 days ago
89%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 7 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
77%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 5 days ago
85%
Aroon
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 5 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DCUSX14.860.03
+0.20%
DWS CROCI US S
DHLRX34.390.06
+0.17%
Diamond Hill Large Cap I
LIGGX11.60-0.04
-0.34%
Loomis Sayles International Growth A
FLCCX47.45-0.27
-0.57%
Fidelity Advisor Large Cap C
TCGRX31.36-0.39
-1.23%
Thornburg Small/Mid Cap Growth R4

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NRIX. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.52%
NRIX - IDYA
61%
Loosely correlated
-0.74%
SYRE - IDYA
61%
Loosely correlated
-1.38%
IMNM - IDYA
60%
Loosely correlated
-3.94%
CGON - IDYA
60%
Loosely correlated
+0.39%
XENE - IDYA
58%
Loosely correlated
+0.28%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-1.38%
IDYA - SYRE
61%
Loosely correlated
-1.52%
CGON - SYRE
60%
Loosely correlated
+0.39%
BEAM - SYRE
58%
Loosely correlated
-2.91%
XNCR - SYRE
57%
Loosely correlated
+0.99%
CRNX - SYRE
55%
Loosely correlated
+1.11%
More